Combination therapies comprising an anti-gitr antibody for treating cancers
OwnerSonia Ioannidis, Nawel Bourayouinventors
Life of this patent
Estimating the term…
Abstract
Methods of treating a cancer by administering to a subject an anti-GITR antibody in combination with at least one of a PD-1 inhibitor (e.g., an anti-PD-1 inhibitor), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody), or a CTLA-4 inhibitor (e.g., an anti-CTLA-4 antibody) are disclosed herein.
Claims37
A method for treating a cancer in a human subject in need thereof, the method comprising administering to the human subject an effective amount of an anti-GITR antibody and an anti-PD-1 antibody, wherein the anti-GITR antibody comprises a heavy chain variable region (VH) comprising a VH CDR1, a VH CDR2, and a VH CDR3, and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VH CDR1 comprises the amino acid sequence of DYAMY (SEQ ID NO:1), the VH CDR2 comprises the amino acid sequence of VIRTYSGDVTYNQKFKD (SEQ ID NO:2), the VH CDR3 comprises the amino acid sequence of SGTVRGFAY (SEQ ID NO:3), the VL CDR1 comprises the amino acid sequence of KSSQSLLNSGNQKNYLT (SEQ ID NO:4), the VL CDR2 comprises the amino acid sequence of WASTRES (SEQ ID NO:
- 5), and the VL CDR3 comprises the amino acid sequence of QNDYSYPYT (SEQ ID NO:6).
-8. (canceled)
The method of claim 7, wherein HNSCC tumor cells in a biological sample obtained from the human subject express GITR.
13-14. (canceled)
(canceled)
-19. (canceled)
-27. (canceled)
-31. (canceled)
-65. (canceled)
-70. (canceled)
-75. (canceled)
-80. (canceled)
-104. (canceled)
A method for treating a cancer in a human subject in need thereof, the method comprising administering to the human subject an effective amount of an anti-GITR antibody and an anti-PD-L1 antibody, wherein the anti-GITR antibody comprises a heavy chain variable region (VH) comprising a VH CDR1, a VH CDR2, and a VH CDR3, and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VH CDR1 comprises the amino acid sequence of DYAMY (SEQ ID NO:1), the VH CDR2 comprises the amino acid sequence of VIRTYSGDVTYNQKFKD (SEQ ID NO:2), the VH CDR3 comprises the amino acid sequence of SGTVRGFAY (SEQ ID NO:3), the VL CDR1 comprises the amino acid sequence of KSSQSLLNSGNQKNYLT (SEQ ID NO:4), the VL CDR2 comprises the amino acid sequence of WASTRES (SEQ ID NO:
- 5), and the VL CDR3 comprises the amino acid sequence of QNDYSYPYT (SEQ ID NO:6).
-112. (canceled)
A method for treating a cancer in a human subject in need thereof, the method comprising administering to the human subject an effective amount of an anti-GITR antibody and an anti-CTLA-4 antibody, wherein the anti-GITR antibody comprises a heavy chain variable region (VH) comprising a VH CDR1, a VH CDR2, and a VH CDR3, and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VH CDR1 comprises the amino acid sequence of DYAMY (SEQ ID NO:1), the VH CDR2 comprises the amino acid sequence of VIRTYSGDVTYNQKFKD (SEQ ID NO:2), the VH CDR3 comprises the amino acid sequence of SGTVRGFAY (SEQ ID NO:3), the VL CDR1 comprises the amino acid sequence of KSSQSLLNSGNQKNYLT (SEQ ID NO:4), the VL CDR2 comprises the amino acid sequence of WASTRES (SEQ ID NO:
- 5), and the VL CDR3 comprises the amino acid sequence of QNDYSYPYT (SEQ ID NO:6).
-198. (canceled)
Dependencies are inferred from the claim text.